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The hypervariable region 1 (HVR1) comprising the first 27 aa of E2 glycoprotein is a target for
neutralizing antibodies against hepatitis C virus (HCV), but the mechanisms of this neutralization
in the cell-culture-infectious genotype 2a strain JFH1 HCV virus (HCVcc) system are unknown.
Two rabbit polyclonal sera, R1020 and R140, recognizing the HVR1 of the genotype 1a isolates
H77c and Glasgow (Gla), respectively, and a Gla HVR1-specific mouse mAb AP213 have been
described previously. However, attempts to generate of antibodies to the JFH1 HVR1 were
unsuccessful. Therefore, this study produced chimeric JFH1 HCVcc viruses harbouring the H77c
or Gla HVR1 to assess the reactivity of antibodies to this region and their effects on virus
infectivity. The inter-genotypic HVR1 swap did not significantly affect virus infectivity. The
genotype 1a HVR1-specific antibodies neutralized chimeric viruses in an isolate-dependent
manner, underlining the role of HVR1 in HCV infection. The neutralizing antibodies reacted mainly
with the C-terminal portion of HVR1, and detailed mapping identified A17, F20 and Q21 in the
Gla HVR1 sequence and T21 (and possibly L20) in the corresponding H77c sequence as key
epitope residues for AP213 and R140, and R1020, respectively. Importantly, none of the
antibodies inhibited in vitro binding of viral envelope glycoproteins to the best-characterized HCV
receptor, CD81, or to the glycosaminoglycan attachment factors. However, the HVR1 antibodies
were capable of post-attachment neutralization. Overall, this study emphasizes the role of HVR1 in
HCVcc entry and provides new tools to study this region further in the context of complete virions.
INTRODUCTION
Hepatitis C virus (HCV) is a major cause of chronic
hepatitis, liver cirrhosis and hepatocellular carcinoma.
Genetic variability, a common feature of RNA viruses, is a
major hindrance in developing effective treatments or
vaccines to fight HCV. Indeed, HCV isolates are classified
into seven distinct genotypes differing at the nucleotide
level by around 30 % and each divided into numerous
subtypes. Moreover, within a single individual, the virus
exists as a constantly evolving quasispecies (Bukh et al.,
1995; Pawlotsky, 2003; Simmonds, 1995).
HCV, a member of the family Flaviviridae, has a positive-
sense RNA encoding a polyprotein, which is cleaved by
cellular and viral proteases into structural and non-structural
proteins (reviewed by Moradpour et al., 2007). The
glycoproteins E1 and E2, which exhibit a high degree of
variability, are responsible for virus cell attachment and
entry. The retroviral HCV pseudoparticle (HCVpp) system
(Bartosch et al., 2003b; Hsu et al., 2003) and more recently the
cell-culture-infectious HCV (HCVcc) system (Lindenbach
et al., 2005; Wakita et al., 2005; Zhong et al., 2005) have shown
that HCV entry into target cells is a complex process involving
virus first binding to low-specificity receptors such as
glycosaminoglycans (Barth et al., 2003) and the low-density
lipoprotein receptor (Agnello et al., 1999). This is followed by
sequential interaction with specific host factors such as CD81,
scavenger receptor class B type I (SR-BI), claudin-1, 6 or 9,
and occludin, leading to entry via the endocytic route (Evans
et al., 2007; Liu et al., 2009; Meertens et al., 2008; Pileri et al.,
1998; Ploss et al., 2009; Scarselli et al., 2002; Zheng et al., 2007).
The E2 glycoprotein is the main target for the antiviral
humoral immune response. Its variability is mostly
confined to the so-called hypervariable regions (HVRs)
Antibody neutralization data is available as supplementary data in JGV
Online.
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(Hijikata et al., 1991; Troesch et al., 2006; Weiner et al.,
1991), which may differ by up to 80 % among HCV
genotypes and even among subtypes of the same genotype.
HVR1, which encompasses the first 27 aa of E2 (residues
384–410 of the viral polyprotein) contains an immunodo-
minant epitope. Antibodies to HVR1 neutralize virus
infection, but the action of this immune pressure on top
of the inherent genetic instability of the virus rapidly selects
resistant variants (Farci et al., 2000; Kurosaki et al., 1993;
Rosa et al., 1996; Shimizu et al., 1994; Weiner et al., 1992;
Zibert et al., 1995). Therefore, antibodies to HVR1 are
typically isolate specific. In contrast, conformational epi-
topes on E2 are less prone to variation and are able to elicit
more broadly neutralizing antibodies in patients (Johansson
et al., 2007; Keck et al., 2007; Law et al., 2008; Mancini et al.,
2009; Owsianka et al., 2008; Perotti et al., 2008; Schofield
et al., 2005). Interestingly, the efficiency of neutralization by
antibodies targeting regions outside HVR1 is altered by
interplay between HVR1, SR-BI and high-density lipopro-
teins (Bartosch et al., 2005; Dreux et al., 2006; Voisset et al.,
2005), emphasizing the role of HVR1 as an immunological
decoy. Nevertheless, HVR1 also plays a role in HCV entry,
possibly mediated by an interaction with SR-BI (Scarselli
et al., 2002) and/or glycosaminoglycans (Barth et al., 2003).
Deletion of HVR1 in HCVpp (Bartosch et al., 2003c) or
HCVcc (Bankwitz et al., 2010) systems, or in virus produced
in chimpanzee (Forns et al., 2000b), results in a significant
loss of infectivity. In addition, anti-HVR1 antibodies have
been shown to be protective in chimpanzees (Farci et al.,
1996). Consistent with a role in entry, some features of
HVR1, such as its overall conformation and the position of
basic residues, are conserved among isolates (Callens et al.,
2005; Penin et al., 2001).
Understanding the mechanisms of antibody-mediated
neutralization is crucial to generate vaccine candidates.
Whilst the mechanisms of cross-reactive neutralizing
antibodies are beginning to be elucidated, the mode of
action of more common isolate-specific neutralizing
antibodies, mainly targeting HVR1, is not well character-
ized. Importantly, there are few data about anti-HVR1
antibody neutralization in the newly described HCVcc
system. Therefore, in this study, the mechanism of anti-
HVR1 antibody neutralization of HCVcc was investigated
using a group of three antibodies in the HCVcc system, and
neutralizing epitopes within HVR1 were characterized.
RESULTS
Generation of anti-HVR1 mAb and polyclonal sera
Two polyclonal antisera, R1020 and R140, were generated by
immunization of rabbits with peptides representing the
HVR1 of two closely related genotype 1a strains, H77c and
Glasgow (Gla), respectively. Furthermore, mAb AP213 was
raised in mice immunized with a recombinant form of HCV
strain Gla E1E2 (Patel et al., 2000). A peptide competition
assay indicated that both R140 and mAb AP213 were HVR1
specific (Fig. 1). Pre-incubation of these antibodies with
peptide 1084.B representing Gla HVR1 (but not the control
peptide 2060.1) prevented recognition of Galanthus nivalis
antigen (GNA)-captured Gla E1E2 in a dose-dependent
manner. As expected, neither of the peptides inhibited
recognition of Gla E1E2 by mAb AP33, a broadly reactive
mAb whose epitope is located immediately downstream of
HVR1 (Owsianka et al., 2001; Tarr et al., 2006). The
specificity of R1020 to strain H77c HVR1 has been
demonstrated previously (Owsianka et al., 2005).
Anti-HVR1 antibodies neutralize the infectivity of
chimeric HCVcc
HVR1 is a target for neutralizing antibodies in natural
infections (Weiner et al., 1992; Zibert et al., 1995) and many
anti-HVR1 antibodies are able to neutralize HCV infections
in vitro and in vivo, as demonstrated in the HCVpp and
chimpanzee models (Bartosch et al., 2003a; Farci et al., 1996;
Hsu et al., 2003). Despite several attempts, we were unable to
raise antibodies against the strain JFH1 HCVcc HVR1. We
showed previously that R1020 was able to neutralize
infection of cells by HCVpp incorporating H77c E1E2
(Owsianka et al., 2005). Similarly, here we found that the
AP213 and R140 antibodies neutralized the infectivity of
HCVpp incorporating H77c E1E2 with Gla HVR1 (see
Methods and Supplementary Table S1, available in JGV
Online). We set out to characterize these antibodies further
using the HCVcc system.
Complete envelope proteins from the Gla strain form non-
functional aggregates (Patel et al., 2000). Therefore, we
generated chimeric JFH1 cDNA in which its HVR1-
encoding region was swapped for the corresponding H77c
or Gla sequence (JFH1-H77cHVR1 or JFH1-GlaHVR1,
respectively) to study the effect of the R1020 or AP213 and
R140 antibodies on HCVcc infection. The viral NS5A
protein was detected in Huh7 cells electroporated with RNA
derived from constructs representing the wild-type (WT)
JFH1 or the JFH1 HVR1 chimeras, but not from the
replication-deficient GND mutant (Wakita et al., 2005),
indicating that the chimeras were replication competent
(Fig. 2a). Moreover, after electroporation, the infectious
virus titres released by both chimeras into cell culture
medium at 2 or 5 days post-electroporation were compar-
able to those for WT JFH1 (Fig. 2b). Next, we monitored the
spread of infection of the WT and chimeric viruses (released
from the electroporated cells) by infecting naı¨ve cells. Huh7
cells infected at an m.o.i. of 0.005 with different viruses were
passaged over a period of 5 weeks. Measurement of the
infectious virus yield in the medium at each passage (Fig. 2c)
showed that the chimeric viruses spread efficiently to naı¨ve
cells, albeit with a slight delay compared with WT JFH1.
Importantly, after seven passages, no mutation was found in
the envelope-encoding region of these infectious chimeric
viruses. Moreover, electroporated cell lysates were tested by
ELISA for reactivity with anti-HVR1 antibodies. As expected,
R1020 serum specifically reacted with JFH1-H77cHVR1
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lysates, and R140 and AP213 antibodies specifically recog-
nized JFH1-GlaHVR1 lysates, whilst AP33 mAb reacted with
both chimeric constructs as well as with WT JFH1 E2 (data
not shown).
Therefore, these chimeric HCVcc were suitable to study the
neutralizing effect of our group of anti-HVR1 antibodies.
mAb AP33, known to inhibit JFH1 infection (Dhillon et al.,
2010; Iro et al., 2009; Tarr et al., 2006; Vieyres et al., 2009),
served as a control and was able to neutralize WT and the
chimeric HCVcc (Fig. 3). However, neutralization of the
chimeric HCVcc was not as potent as for WT JFH1, with at
least a tenfold increase in the IC50 value. R1020 IgGs
neutralized JFH1-H77cHVR1 virus and to a lesser extent
the heterologous JFH1-GlaHVR1 virus in a dose-depen-
dent fashion. mAb AP213 and R140 IgGs neutralized only
the JFH1-GlaHVR1 virus.
Stringent isolate specificity of anti-HVR1
antibodies
To gain further insights into the role of HVR1 in HCV
infection, we set out to identify the amino acid residues
critical for interaction with our anti-HVR1 antibodies.
First, the reactivity of anti-HVR1 antibodies was assessed
against a panel of 25 E1E2 constructs representing the six
major genotypes of HCV, with non-redundant HVR1
sequences (Lavillette et al., 2005; Owsianka et al., 2005)
(Fig. 4). Expression of 20 of these clones was validated by
strong reaction with AP33 mAb in ELISA and these clones
were therefore kept for further analysis. The AP213 and
R140 antibodies reacted only with the Gla strain.
Interestingly, residue Q21 was the only Gla-specific residue
in this panel of HVR1 sequences and could account for the
restricted isolate-specificity of the AP213 and R140
antibodies. In contrast, some cross-reactivity was observed
for the R1020 antiserum, which weakly recognized some
strains belonging to genotypes 1a and 2b. Interestingly, the
presence of the L20 residue seemed to correlate with some
epitope recognition as it was present in the H77c HVR1 as
well as in four of the six clones weakly recognized by R1020
IgGs, but absent from all the negative clones. Only residue
N8 was H77c specific, and this could explain the strong
reactivity of the R1020 antiserum with this strain.
Together, these data confirmed the isolate specificity of
our anti-HVR1 antibodies.
Fig. 1. Peptide competition assay. mAbs AP33 and AP213 and the rabbit antiserum R140 were incubated with a range of
concentrations of HVR1-derived (1084.B; filled bars) or irrelevant (2060.1; shaded bars) peptide. The reactivity of the peptide/
antibody mixture for H77c-GlaHVR1 E1E2 (see Methods) was then tested by GNA capture ELISA.
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AP213 mAb epitope mapping by phage display
We next used the phage display technique to map more
precisely the epitope residues recognized by our antibodies.
Because R1020 and R140 are polyclonal antibodies and this
method is more suitable for mAbs, we restricted our
analysis to mAb AP213. Following three rounds of affinity
selection against mAb AP213, 32 peptide sequences were
isolated (Fig. 5). Overall, the frequency of phenylalanine
(F), lysine (K) and proline (P) residues present in the
HVR1 sequence was significantly increased in the selected
peptides compared with the original library (at least
doubled), suggesting that they were indeed selected during
panning. The sequences were arranged into three groups.
In groups A (nine clones) and B (12 clones), a glutamine
residue (Q) was strictly conserved, often preceded by a
large aromatic residue [tyrosine (Y) or tryptophan (W) in
group A and phenylalanine (F) in group B] and sometimes
followed by a proline residue (four sequences). Finally,
group C (11 clones) exhibited an ‘FGP’ motif in all but one
clone, which resembled again the ‘FQP’ motif in the Gla
HVR1. We also found an overall frequent repetition of
basic residues [lysine (K), arginine (R) and histidine (H)],
often aligning with K25 in HVR1. Although heterogeneous,
Fig. 2. Chimeric HCVcc with genotype 1a HVR1 is infectious. (a) JFH1 chimeras were shown to replicate in Huh7 cells. Cells
were fixed at 48 h after electroporation with the different constructs, stained for nuclei (DAPI; top row) and for NS5A (bottom
row), and analysed by confocal microscopy. Bars, 200 mm. (b) Infectivity of the cell supernatant, assessed at 2 or 5 days after
electroporation with JFH1 chimeras. Filled bars, WT JFH1; light grey bars, JFH1-H77cHVR1; dark grey bars, JFH1-GlaHVR1.
(c) Production of infectious chimeric virus after infection of naı¨ve Huh7 cells. Naı¨ve cells infected at a low m.o.i. with supernatant
from electroporated cells were serially passaged and infectious virus yields were measured in the cell supernatant at each
passage by TCID50 assay. $, WT JFH1; #, JFH1-H77cHVR1; ., JFH1-GlaHVR1.
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these data suggest that the 20FQPXXK25 motif in HVR1 is a
key element in mAb AP213 binding.
The C-terminal moiety of HVR1 is the main
determinant for anti-HVR1 antibody binding
To delineate the epitope region of all three anti-HVR1
antibodies, a panel of E1E2 mutants was generated in a
phCMV vector. They encoded, in an H77c background, a
chimeric HVR1 consisting of the H77c HVR1 N terminus
and the Gla HVR1 C terminus (HG chimera) or the Gla
HVR1 N terminus and the H77c HVR1 C terminus (GH
chimera) (Fig. 6a). Reactivity with mAb AP33 and the
conformation-sensitive mAb H53 suggested that the
protein expression levels and global conformation were
similar to those for the parental (H77c) constructs (Fig. 6b,
c). The chimeras were also functional in the HCVpp
system, with at least 50 % of the infectivity of the parental
strain preserved (data not shown). Nevertheless, differences
in affinity for anti-HVR1 antibodies were observed. R1020
serum, specific for the H77c HVR1, did not recognize the
HG chimera but reacted with the GH chimera (Fig. 6d).
Importantly, residue N8, which was H77c specific (see Fig.
4 and above), was therefore not necessary for R1020 IgG
binding. The Gla HVR1-specific mAb AP213 only
recognized the HG chimera (Fig. 6e). Lastly, the R140
serum bound both constructs, with an increased affinity for
the HG chimera (Fig. 6f). This indicated that the HVR1 C
terminus was involved in antibody binding and strain
specificity of all three antibodies, whilst the HVR1 N
terminus was not sufficient for binding. Importantly,
antibody affinity for the HVR1 chimeras was always lower
than for the parental homologous complete HVR1. In
addition, the spectrum of antibody neutralization towards
HCVpp harbouring chimeric HVR1 (HG or GH chimeras;
see Supplementary Table S1) correlated with the antibody
affinity as assayed by ELISA (Fig. 6). Therefore, our anti-
HVR1 antibodies reacted principally with the C-terminal
moiety of HVR1, although the N-terminal portion may be
important for HVR1 global conformation and optimal
antibody binding affinity.
Single point mutants in HVR1 highlight residues
important for antibody binding
Each of the eight residues differing between the H77c and
Gla HVR1 sequence (Fig. 6a) were individually mutated, in
the H77c–Gla HVR1 sequence, to their H77c counterpart.
Antibody binding to these mutants was then analysed (Fig.
6b–e). None of these mutations significantly affected the
protein expression levels (mAb AP33 binding) or the
affinity for the conformation-sensitive mAb H53. However,
mutation of F20 and Q21 into the H77c residue resulted in
a complete loss of affinity for AP213 mAb (Fig. 6e).
Moreover, the A17V mutation significantly decreased the
Gla HVR1 affinity for both the AP213 and R140 antibodies
(Fig. 6e, f). Conversely, a single point mutation in the Gla
HVR1 sequence (Q21T) could restore some affinity for
Fig. 3. Anti-HVR1 antibodies neutralize chimeric HCVcc infection. (b) HCVcc harbouring the JFH1 (#), H77c ($) or Gla (m)
HVR1 were incubated with a range of concentrations of anti-HVR1 or control antibodies prior to infection of naı¨ve Huh7 cells. At
2 days post-infection (p.i.), infectivity was evaluated by f.f.u. assay. The residual infectivity relative to infectivity in the absence of
antibody is shown.
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R1020 antibody, which is H77c specific, indicating that
residue T21 plays an important part in the R1020 epitope.
Anti-HVR1 antibodies are partially conformation
sensitive
To test whether anti-HVR1 antibodies were conformation
sensitive, their affinity for native or denatured E1E2 captured
on GNA-coated plates was determined (Fig. 7). As expected
(Cocquerel et al., 1998), the conformation-sensitive mAb
H53 specifically recognized native H77c E1E2. The affinity of
mAb ALP98 for both H77c and H77c-GlaHVR1 E1E2 was
only mildly affected by antigen denaturation. As shown
previously (Tarr et al., 2006), mAb AP33 exhibited partial
conformation sensitivity for both antigens, although its
epitope is linear. Interestingly, although two of them were
raised against peptides, all three anti-HVR1 antibodies were
also partially conformation sensitive. Of note, the peptides
used to raise the R1020 and R140 antisera were relatively
long (27 and 21 residues, respectively) and might fold in
solution.
Anti-HVR1 antibodies are capable of post-
attachment neutralization
To determine whether anti-HVR1 antibodies act by
inhibiting HCVcc attachment or at a post-binding entry
step, three protocols were used (Fig. 8, and see Methods) to
distinguish between these events. Protocol C, in particular,
measured post-attachment neutralization. mAb AP33 was
efficient at inhibiting entry in protocol C, showing that this
mAb was capable of post-attachment neutralization, as
reported previously (Haberstroh et al., 2008). Nevertheless,
AP33-mediated neutralization was more efficient in
protocol B, suggesting an additional effect of this antibody
in attachment inhibition or that its epitope was more
readily available before virus attachment. Interestingly,
Fig. 4. Reactivity of anti-HVR1 antibodies with a panel of patient-
derived E1E2 glycoproteins. A panel of E1E2 constructs (Lavillette
et al., 2005; Owsianka et al., 2005) was expressed in HEK cells
and the cell lysates analysed by GNA ELISA for their recognition
by anti-HVR1 antibodies. HVR1 sequences were aligned with the
H77c (top panel) or Gla (bottom panel) HVR1 sequence and
identical residues are shaded in grey. Residues specific for the
H77c or Gla HVR1 are boxed. Clones were classified into three
groups depending on whether they were non-reactive (–), weakly
reactive (+/”) or strongly reactive (+) with anti-HVR1 antibodies in
the linear range of the assay.
Fig. 5. Epitope mapping of mAb AP213 by peptide phage display.
A total of 32 peptides were selected after three rounds of panning
of a random peptide phage display library against mAb AP213.
Their amino acid sequence was aligned manually with the Gla
HVR1 sequence. Residues in bold black represent residues
present in the HVR1 sequence, aligned with or close to (italics)
the HVR1 residue. Residues in bold grey are residues aligned with
HVR1 residues having similar properties.
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Fig. 6. Reactivity of anti-HVR1 antibodies for a panel of E1E2mutants. (a) Amino acid sequences of the H77c, Gla and chimeric HG
or GH HVR1 (see Methods). Residues in bold differ between the H77c and Gla HVR1 sequence. All mutants were generated in the
H77c-GlaHVR1 background. Clones A8N to Q21T consisted of H77c-GlaHVR1 E1E2 with single mutations in HVR1 replacing a
residue from the Glasgow strain by its H77c counterpart. (b–f) Serially diluted lysates of HEK cells transfected with different E1E2
constructs were tested for recognition by different antibodies byGNA capture ELISA. For each antibody, a lysate dilutionwas chosen
that gave absorbance readings in a linear range, and absolute absorbance values (at 450 nm) were plotted.
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anti-HVR1 antibodies behaved similarly to mAb AP33 in
that they were capable of post-attachment neutralization
but were more efficient at inhibiting HCVcc entry when
present during the virus-binding stage. It should be noted
that the antibodies were used at suboptimal concentrations
so that the differences in neutralization between protocols
B and C could be observed more easily, but up to 80 %
post-attachment neutralization could be obtained with
anti-HVR1 antibodies used at higher concentrations (data
not shown). Also, because antibodies were used at
suboptimal concentrations, more efficient neutralization
was observed in protocol A where antibody was added
twice in the experiment. Consistent with their role in
binding inhibition (Chang et al., 2007; Koutsoudakis et al.,
2006), heparin and the anti-ApoE serum were more
efficient in protocol C. Note that we did observe some
post-attachment neutralization with heparin that could
correspond to the elution of a fraction of the cell-bound
viruses. This effect was weaker or undetected in previous
reports (Haberstroh et al., 2008; Koutsoudakis et al., 2006;
Zeisel et al., 2007), possibly due to the use of different virus
strains (Luc-Jc1 versus JFH-1 virus). In contrast, anti-
CD81 mAb had similar effects in protocols B and C,
consistent with the established role of CD81 in a post-
attachment step of entry. Similar results were obtained with
the HCVpp system (data not shown).
DISCUSSION
Anti-HVR1 antibodies neutralize chimeric HCVcc
Anti-HVR1 antibodies are generally isolate specific, and, to
our knowledge, no animal-raised anti-HVR1 antibody has
been obtained against the genotype 2a HCVcc JFH1 isolate.
HVR1 plays a crucial role in virus entry and is a major
target of the neutralizing antibody response in vivo.
Therefore, the lack of information on anti-HVR1 anti-
body-mediated neutralization represents a significant gap
in our understanding of the mechanics of virus entry.
In this study, we investigated the role of HVR1 in HCVcc
entry and the mechanisms of antibody-mediated neutral-
ization against this region. First, functional HCVcc was
generated with heterologous genotype 1a HVR1. Whilst
HVR1 deletion drastically impairs HCV infectivity
(Bankwitz et al., 2010; Bartosch et al., 2003c; Forns et al.,
2000b; Wakita et al., 2005), this inter-genotypic swap in
HVR1 had little effect on virus infectivity, consistent with
the flexibility of this segment, its relative independence
from the rest of E2 (Forns et al., 2000a; McCaffrey et al.,
2007) and its tolerance to certain mutations. These
chimeras were therefore suitable tools to study the effect
of a panel of anti-HVR1 antibodies on HCVcc infectivity as
they were raised against genotype 1a HVR1.
The anti-HVR1 antibodies inhibited HCV infection in the
HCVpp and HCVcc systems in an isolate-specific manner.
Interestingly, their epitopes mapped mostly to the C-
terminal part of HVR1, consistent with a HVR1 model
where the neutralization determinants are located in this
portion and not in the less variable N-terminal part.
Indeed, for example, the rat anti-HVR1 mAbs 6/16, 7/59, 6/
82 (reactive against HVR1 N-terminal part) and 9/86
(recognizing the whole HVR1) do not neutralize HCVpp
infectivity (Hsu et al., 2003). However, mAb 9/27, whose
epitope includes the C-terminal part of HVR1 (Flint et al.,
2000), neutralizes HCVpp infection (Bartosch et al., 2003a;
Hsu et al., 2003). This antibody also blocks binding of
soluble E2 to SR-BI. The mAbs 2P24 and 15H4 recognize
an epitope within the HVR1 C terminus (23GXXQ26 motif)
and inhibit HCV serum particles binding to MOLT-4 cells
(Li & Allain, 2005; Li et al., 2001). In keeping with the
latter, our phage display mapping data indicated that the
20FQPXXK25 motif is a key element of the mAb AP213
epitope. Lastly, statistical analyses have suggested the
presence of two immunogenic domains on HVR1 (Penin
et al., 2001): the first region encompassing the 14 first
residues of HVR1 and the second region starting from
residue 17. The compiled data obtained with various anti-
HVR1 antibodies suggested that the second region is the
main neutralization determinant in HVR1.
Fig. 7. Conformation sensitivity of anti-HVR1 antibodies. Native or
denatured HEK cell lysates expressing the H77c (top panel) or
H77c-GlaHVR1 (bottom panel) E1E2 were captured on GNA-
coated plates and tested for recognition by different antibodies.
For each antibody, a lysate dilution was chosen that gave
absorbance readings in a linear range and absolute absorbance
values (at 450 nm) were plotted.
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Further fine mapping identified the residues A17, F20
and Q21 in the Gla HVR1 sequence and T21 (and
possibly L20) in the corresponding H77c sequence as
essential for the AP213 and R1020 epitopes, respectively.
Residue A17 was also crucial for the reactivity of R140 to
Gla HVR1. Whether these residues are involved directly
in antibody–antigen interaction or whether they are
essential to confer an appropriate configuration to the
antigen is unknown. However, this fits with the
interaction interface model whereby a small number of
hydrophobic residues, which are rare in HVR1, would
constitute the contact points between two proteins, this
hotspot for binding energy being surrounded by a more
hydrophilic region exposed to the aqueous solution
(Clackson & Wells, 1995).
Mechanisms of neutralization by anti-HVR1
antibodies
Anti-HVR1 antibodies had very little effect in vitro on CD81
binding and no effect on heparin binding (data not shown).
This region has never been implicated in direct CD81
binding, although it was shown to modulate it (Bankwitz
et al., 2010; Roccasecca et al., 2003). Consistently, we
observed that mAb AP33 neutralization (which inhibits the
E2–CD81 interaction) and also inhibition with a soluble
Fig. 8. Anti-HVR1 antibodies are capable of post-attachment neutralization. (a) Schematic representation of the protocols used
to distinguish between binding and entry stages of HCVcc entry (see Methods). Arrows correspond to the addition of inhibitors.
The # symbol indicates that the inhibitor was pre-incubated with the appropriate HCVcc (heparin, 500 mg ml”1; anti-ApoE
serum, 1 : 150; mAb AP33, 20 mg ml”1; mAb AP213, 20 mg ml”1; R1020 IgGs, 30 mg ml”1; R140 IgGs, 30 mg ml”1) or with
the cells (anti-CD81 antibody at 5 mg ml”1) for 30 min at 37 6C before virus inoculation. Ab, Antibody. (b) HCVcc infectivity
was assessed after adding the inhibitors at different stages of the entry process, according to protocols A, B and C. Infectivity
was assessed by f.f.u. assay at 48 h p.i. and plotted as the percentage of infectivity observed in the absence of inhibitor.
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form of CD81 (data not shown) were significantly
attenuated with JFH1 HVR1 chimeras, although we could
not detect any difference in mAb AP33 affinity for E1E2
extracted from infected cells (data not shown). Swapping the
HVR1 loop might therefore increase the steric hindrance
around the CD81-binding site, a phenomenon possibly
accentuated at the surface of virus particles where glyco-
proteins might be more tightly packed together.
Similarly to mAb AP33, anti-HVR1 antibodies were capable
of post-attachment neutralization, but were more efficient
when present during the virus-binding stage. This could
suggest that anti-HVR1 antibodies also inhibit virus binding
or that their epitope is more available before virus
attachment. Interestingly, we quantified viral RNA bound
to the cell surface at 4 uC and found that attachment was not
significantly affected by virus pre-incubation with anti-
HVR1 antibodies (data not shown) but was strongly
inhibited by heparin treatment (Vieyres et al., 2009).
Although one might expect an attenuated binding to SR-
BI in presence of anti-HVR1 antibodies, it is likely that
binding occurs mainly via virus-associated lipoproteins and
is therefore not blocked by anti-HVR1 antibodies. Thus, the
role of HVR1 in HCV infection is not limited to cell-surface
attachment, through glycosaminoglycans binding for
instance (Barth et al., 2006; Basu et al., 2004); on the
contrary, this region seems to play an active role in entry.
In conclusion, the chimeric HCVcc constructs and anti-
HVR1 antibodies described here constitute new tools to
investigate further the role of HVR1 in the HCV life cycle.
Antibodies targeting the HVR1 C terminus were able to
neutralize HCVcc infectivity and notably inhibited a post-
attachment step of entry, unravelling new roles for HVR1
in HCVcc infection.
METHODS
Cell culture and antibodies. Human hepatoma Huh7 cells
(Nakabayashi et al., 1982) and human epithelial kidney (HEK)
293T cells (ATCC CRL-1573) were propagated as described elsewhere
(Vieyres et al., 2009). The mouse mAbs AP213, AP33, ALP98 and H53
and the rabbit polyclonal serum R1020 have been described
previously (Clayton et al., 2002; Cocquerel et al., 1998; Owsianka
et al., 2005; Patel et al., 2000). The rabbit polyclonal antiserum R140
was raised against a synthetic peptide (1084.B; see below) corre-
sponding to the HCV genotype 1a strain Gla HVR1, as described
previously (Patel et al., 2000). The rabbit serum R1353 directed
against an irrelevant protein was used as a control. The mouse
monoclonal and sheep polyclonal anti-HCV NS5A antibodies were
kind gifts from C. M. Rice and M. Harris, respectively (Lindenbach
et al., 2005; Macdonald et al., 2003). Anti-CD81 mAb (clone JS-81)
and anti-ApoE serum were obtained from BD Biosciences and
Millipore, respectively. Alexa Fluor 488-conjugated donkey anti-
mouse and anti-rabbit antibodies were purchased from Invitrogen.
HRP-conjugated protein A or antibodies were from Sigma. Total IgGs
from R1020, R140 and R1353 sera were purified using protein G
affinity chromatography for use in neutralization assays.
Plasmid constructs. Plasmid phCMVcE1E2(H77c) encoding the
full-length E1E2 of the genotype 1a strain H77c (Yanagi et al., 1997)
has been described previously (Owsianka et al., 2005). The HVR1 (aa
384 – 410 of the viral polyprotein) in the E2 gene of this plasmid was
replaced with the corresponding sequence of the genotype 1a Gla
strain to form plasmid phCMVcE1E2(H77c-GlaHVR1). This plasmid
also carried an A373V amino acid substitution in the H77c E1 gene.
Chimeric HVR1 sequences were generated by fusion PCR and
inserted into phCMVcE1E2(H77c). Point mutants in HVR1 were
generated in the phCMVcE1E2(H77c-GlaHVR1) plasmid using a
QuikChange II Site-directed Mutagenesis kit (Stratagene). E1E2-
encoding plasmids were expressed by transfection of HEK cells and
cell lysates were harvested 3 days later.
The plasmid pUC-JFH1 carries the full-length cDNA of the genotype
2a HCVcc strain JFH1 (Wakita et al., 2005). The plasmid pUC-JFH1/
GND is identical except that it carries the replication knockout GND
mutation in the NS5B-encoding sequence (Wakita et al., 2005).
Chimeric JFH1 genomic cDNAs were constructed that carried the Gla
or H77c HVR1 in the plasmid pUC-JFH1. All constructs were
checked by restriction analysis and nucleotide sequencing of the
E1E2-encoding region.
Generation of HCVcc and infectivity assays. HCVpp and HCVcc
were generated essentially as described previously (Bartosch et al.,
2003b; Kato et al., 2006). Briefly, linearized in vitro-transcribed HCV
genomic RNA was electroporated into Huh7 cells. Cells were split at
2 days post-electroporation. The filtered supernatant harvested at
5 days post-electroporation was titrated and used to infect naı¨ve cells
at an m.o.i. of 0.005. These infected cells were serially passaged and
the supernatant evaluated for virus infectivity at each passage. High-
titre stocks were generated from infected cells at passages 5–7, titrated,
stored in aliquots at 270 uC and used in neutralization experiments.
In addition, 105 naı¨ve Huh7 cells were infected in six-well dishes with
these virus stocks and total RNA was extracted after 3 days. HCV
RNA corresponding to the E1E2-encoding region was reverse
transcribed and amplified by PCR. The cDNA fragments obtained
were purified on gels and sequenced to check for the appearance of
adaptive mutations.
HCVcc infectivity was assessed as described previously by TCID50 or
f.f.u. methods (Lindenbach et al., 2005; Zhong et al., 2005). In both
cases, cells were fixed in methanol 2 days p.i. and immunostained for
NS5A using mAb 9E10 or sheep anti-NS5A antiserum.
Binding/entry assay. Three protocols were used to determine
whether anti-E2 antibodies inhibited virus attachment to the cells or
acted post-binding. In protocol A, HCVcc was pre-incubated for
20 min at 37 uC with antibody, chilled briefly and then adsorbed onto
pre-cooled target cells for 1 h at 4 uC. Unbound virus was removed
by washing the cells twice with cold medium. Antibody was added
again to the culture for 10 min at 4 uC, after which the cells were
shifted to 37 uC to allow HCV entry to occur. In protocols B and C,
antibody was only added reciprocally before or after HCVcc binding,
respectively. Anti-CD81 mAb was pre-incubated with the cells rather
than with HCVcc. The inoculum was replaced with fresh medium
after 3 h at 37 uC. At 2 days p.i., cells were fixed and stained for
counting of f.f.u.
GNA capture ELISA. Detection of E2 glycoprotein by ELISA was
performed essentially as described previously (Patel et al., 2000).
Briefly, E1E2 glycoproteins from clarified lysates of transfected HEK
cells were captured onto GNA lectin-coated ELISA plates (Immulon
2HB; Thermo Electro Corp.). The bound glycoproteins were detected
with specific anti-E2 antibodies, followed by HRP-conjugated anti-
species IgG and 3,39,5,59-tetramethylbenzidine substrate (Invitrogen).
Reactions were stopped with 0.5 M H2SO4 and absorbance values
were determined at 450 nm. To test for conformation sensitivity of
antibody epitopes, HEK cells expressing E1E2 were lysed in PBS by
freeze-thawing and sonication. Clarified cell lysates were either left
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untreated (native E1E2) or boiled for 10 min in the presence of SDS
(0.1 % final) and DTT (20 mM final) (denatured E1E2). NP-40 was
added to both native and denatured samples at a final concentration
of 1 %. The glycoproteins were then captured on GNA-coated plates
and tested for antibody recognition as described above.
Peptide competition assay. Branched peptides 1084.B [residues
390–410 of HCV strain Gla HVR1: (GAAARSTLQLAGLFQPGA-
KQN)4K3A] and 2060.10 [residues 604–621 of HCV strain H77c E2:
(TPRCMVDYPYRLWHYPCT)4K3A] were incubated in a range of
concentrations with mAbs AP33 and AP213 or R140 antiserum at
room temperature for 30 min. The peptide/antibody mix was then
tested for reactivity against GNA-captured H77c-GlaHVR1 E1E2 in
an ELISA as described above.
AP213 epitope mapping by random peptide phage display. A
PhD-12 Phage Display Peptide Library kit (New England Biolabs) was
used according to the manufacturer’s instructions. Briefly, the peptide
library was enriched for mAb AP213-specific peptides by three rounds
of panning. At each round, phages were incubated in a well of an
Immulon 2HB plate (Thermo Electro Corp.) coated with 10 mg mAb
AP213 ml21 and bound phages were eluted in low-pH buffer. After
the third round of panning, 52 eluted phages were isolated, amplified
and tested by ELISA for their reactivity with mAb AP213 or an isotype
control (mAb AP33). The DNA sequence of 32 AP213-specific phages
was determined following the manufacturer’s instructions. The
deduced peptide sequences were aligned with that of Gla E1E2 using
CLUSTAL W and the alignment with Gla HVR1 was further adjusted
manually.
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